Single-Dose Kinetics of Recombinant Human Erythropoietin after Intravenous, Subcutaneous and Intraperitoneal Administration

2015 ◽  
pp. 106-111 ◽  
Author(s):  
D. Kampf ◽  
A. Kahl ◽  
J. Passlick ◽  
A. Pustelnik ◽  
K. -U. Eckardt ◽  
...  
Keyword(s):  
Single Dose ◽  
Recombinant Human Erythropoietin ◽  
Intraperitoneal Administration ◽  
Human Erythropoietin ◽  
Kinetics Of

Intraperitoneal Administration of Recombinant Human Erythropoietin

1992 ◽  
Vol 12 (4) ◽  
pp. 378-383 ◽  
Author(s):  
Leon A.M. Frenken ◽  
Dirk G. Struijk ◽  
Peter J.W. Coppens ◽  
Roland G.W.L. Tiggeler ◽  
Raymond T. Krediet ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Intraperitoneal Administration ◽  
Subcutaneous Administration ◽  
Hemoglobin Concentration ◽  
Treated Group ◽  
Efficacy And Safety ◽  
University Hospitals ◽  
Safe Alternative ◽  
Human Erythropoietin ◽  
Dialysis Solution

Objective To determine the efficacy and safety of intraperitoneal administration of recombinant human erythropoietin (rHuEPO) in continuous ambulatory peritoneal dialysis (CAPD) patients compared to subcutaneous rHuEPO. Design Prospective analysis of an open, nonrandomized investigation. Setting Outpatient CAPD clinics in two university hospitals. Patients Nine adult CAPD patients receiving rHuEPO intraperitoneally and 8 patients receiving rHuEPO sub-cutaneously. Intervention One hundred units of rHuEPO per kilogram of body weight were administered three times a week for 8 weeks or until the target hematocrit of 35% was reached. Thereafter, dosages of rHuEPO were adjusted for response. Intraperitoneal rHuEPO was administered in 1 L of dialysis solution during the night. Measurements Efficacy was assessed by measuring the increase in hemoglobin. Tolerance was assessed by monitoring side effects. Results In the first 8 weeks of treatment hemoglobin concentration increased from 64.5±12.9 glL to 98.3±16.1 g/L (p<0.0005) in the intra peritoneally treated group. In the subcutaneously treated group hemoglobin increased significantlyfaster (p<0.05) from 72.5±4.8 g/L to 119.2±11.3 g/L (p<0.0005) in the same period. Antihypertensive medication had to be increased or instituted in most of the patients in both groups. The incidence of peritonitis in the intraperitoneally treated group was not increased when compared to the pretreatment incidence. Conclusions Subcutaneously administered rHuEPO is superior to intraperitoneally administered rHuEPO with regard to the required dosages. However, the results of this study show that intraperitoneal administration of rHuEPO might be a convenient and safe alternative when subcutaneous administration is undesirable.

Intraperitoneal Administration of Recombinant Human Erythropoietin in Uremic Animals

1988 ◽  
Vol 8 (4) ◽  
pp. 249-252 ◽  
Author(s):  
Joanne M. Bargman ◽  
Andre Breborowicz ◽  
Helen Rodela ◽  
Kostas Sombolos ◽  
Dimitrios G. Oreopoulos
Keyword(s):  
Peritoneal Dialysis ◽  
End Stage Renal Disease ◽  
Recombinant Human Erythropoietin ◽  
Dialysis Patient ◽  
Intraperitoneal Administration ◽  
Peritoneal Dialysis Patient ◽  
Human Erythropoietin ◽  
Stage Renal Disease ◽  
Almost All ◽  
End Stage

Previous protocols of administration of recombinant human erythropoietin to patients with end-stage renal disease have been by the i.v. route. Because this method would be impractical for the continuous ambulatory peritoneal dialysis patient, we designed an i.p. dosing protocol in uremic rabbits to examine whether significant amounts of this hormone could be absorbed from the peritoneal cavity. Our results demonstrate that almost all of the erythropoietin is absorbed (or adsorbed) during a prolonged dwell when administered undiluted by dialysate.

The Efficacy of Preoperative Administration of a Single Dose of Recombinant Human Erythropoietin in Pediatric Cardiac Surgery

2007 ◽  
Vol 10 (2) ◽  
pp. E115-E119 ◽  
Author(s):  
Yoshio Ootaki ◽  
Masahiro Yamaguchi ◽  
Naoki Yoshimura ◽  
Shigeteru Oka ◽  
Masahiro Yoshida ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Single Dose ◽  
Recombinant Human Erythropoietin ◽  
Pediatric Cardiac Surgery ◽  
Human Erythropoietin ◽  
Preoperative Administration

scholarly journals Single-dose Pharmacokinetics of Recombinant Human Erythropoietin in Patients with Various Degrees of Renal Failure

1989 ◽  
Vol 4 (5) ◽  
pp. 345-349 ◽  
Author(s):  
J. Kindler ◽  
K.-U. Eckardt ◽  
B. Ehmer ◽  
K. Jandeleit ◽  
A. Kurtz ◽  
...  
Keyword(s):  
Renal Failure ◽  
Single Dose ◽  
Recombinant Human Erythropoietin ◽  
Human Erythropoietin
Sign in / Sign up

Export Citation Format

Share Document